Author

Guillen Nieto Gerardo

Biomedical Research Director, Center for Gen

Biography

Guillen Nieto Gerardo works at Department of Biotechnology, Center for Genetic Engineering and Biotechnology, Havana, Cuba. His area of research interests includes Infectious diseases, virology. He /she has authored of many research articles/books in relevant areas.
Title
Cited by
Year
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA …
F Hernández-Bernal, MC Ricardo-Cobas, Y Martín-Bauta, ...EClinicalMedicine 46, 2022202
32
2022
CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients
M Hernandez-Cedeño, R Venegas-Rodriguez, R Peña-Ruiz, ...Cell Stress and Chaperones , 515-525, 2021202
26
2021
Wound chronicity, impaired immunity and infection in diabetic patients
N Rodríguez-Rodríguez, I Martínez-Jiménez, A García-Ojalvo, ...MEDICC review 24, 44-58, 2022202
25
2022
The microglial NLRP3 inflammasome is involved in human SARS-CoV-2 cerebral pathogenicity: A report of three post-mortem cases
VF Cama, J Marín-Prida, N Acosta-Rivero, EF Acosta, LO Díaz, ...Journal of Neuroimmunology 361, 577728, 2021202
23
2021
Sustained antiviral and liver protection by a nasal therapeutic vaccine (NASVAC, Containing Both HBsAg and HBcAg) in patients with chronic hepatitis B: 2-year follow-up of …
SMF Akbar, M Al Mahtab, JC Aguilar, O Yoshida, E Penton, GN Gerardo, ...Pathogens 10 (11), 1440, 2021202
18
2021
Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study
PI Más-Bermejo, FO Dickinson-Meneses, K Almenares-Rodríguez, ...The Lancet Regional Health–Americas 16, 2022202
17
2022
The SARS-CoV-2 receptor-binding domain expressed in Pichia pastoris as a candidate vaccine antigen
M Limonta-Fernández, G Chinea-Santiago, AM Martín-Dunn, ...MedRxiv, 2021.06. 29.21259605, 2021202
15
2021
The safety and efficacy of a therapeutic vaccine for chronic hepatitis B: a follow-up study of phase III clinical trial
SMF Akbar, M Al Mahtab, JC Aguilar, O Yoshida, S Khan, E Penton, ...Vaccines 10 (1), 45, 2021202
15
2021
An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen
M Limonta-Fernández, G Chinea-Santiago, AM Martín-Dunn, ...New Biotechnology 72, 11-21, 2022202
12
2022
Epidermal growth factor in healing diabetic foot ulcers: From gene expression to tissue healing and systemic biomarker circulation
J Berlanga-Acosta, H Camacho-Rodríguez, Y Mendoza-Marí, ...MEDICC review 22, 24-31, 2022202
12
2022
In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 …
LA Espinosa, Y Ramos, I Andújar, EO Torres, G Cabrera, A Martín, ...Analytical and Bioanalytical Chemistry 413 (30), 7559-7585, 2021202
11
2021
Diagnostic accuracy of blood-based biomarker panels: a systematic review
A Hardy-Sosa, K León-Arcia, JJ Llibre-Guerra, J Berlanga-Acosta, ...Frontiers in aging neuroscience 14, 6369, 2022202
8
2022
A recombinant SARS-CoV-2 receptor-binding domain expressed in an engineered fungal strain of Thermothelomyces heterothallica induces a functional immune response in mice
L Lazo, M Bequet-Romero, G Lemos, A Musacchio, A Cabrales, AJ Bruno, ...Vaccine 40 (), 1162-1169, 2022202
8
2022
Scalable bio marker combinations for early stroke diagnosis: A systematic review
SC Baez, D Garcia del Barco, A Hardy-Sosa, G Guillen Nieto, ...Frontiers in neurology 12, 63693, 2021202
8
2021
In-solution buffer-free digestion for the analysis of SARS-CoV-2 RBD proteins allows a full sequence coverage and detection of post-translational modifications in a single ESI …
LA Espinosa, Y Ramos, I Andújar, EO Torres, G Cabrera, A Martín, ...BioRxiv, 2021.05. 10.443404, 2021202
7
2021
Elevated antibody titers in Abdala vaccinees evaluated by Elecsys® anti-SARS-CoV-2 S highly correlate with UMELISA SARS-CoV-2 ANTI RBD, ACE-2 binding inhibition and viral …
G Lemos-Pérez, S Chávez-Valdés, H González-Formental, ...MedRxiv, 2021.10. 18.212519, 2021202
6
2021
HeberNasvac, a therapeutic vaccine for chronic hepatitis b, stimulates local and systemic markers of innate immunity: Potential use in SARS-CoV-2 postexposure prophylaxis
YA Fleites, J Aguiar, Z Cinza, M Bequet, E Marrero, M Vizcaíno, I Esquivel, ...Euroasian Journal of Hepato-Gastroenterology 11 (2), 9, 2021202
5
2021
Intranasal therapeutic vaccine containing HBsAg and HBcAg for patients with chronic hepatitis B; 18 months follow‐up results of phase IIa clinical study
O Yoshida, SMF Akbar, Y Imai, T Sanada, K Tsukiyama‐Kohara, ...Hepatology Research 3 (3), 196-207, 2023202
5
2023
Long term HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg and HBcAg mixed with mucoadhesive CVP (CVP-NASVAC) in patients with chronic HBV …
O Yoshida, Y Imai, K Shiraishi, T Sanada, M Kohara, K Tsukiyama-Kohara, ...Hepatology 74, 64A-64A, 2021202
3
2021
CIGB-258, péptido inhibidor de la hiperinflamación en pacientes con COVID-19
MC Domínguez Horta, R Venegas Rodríguez, G Guillén Nieto, ...Anales de la Academia de Ciencias de Cuba 12 (1), 2022202
3
2022

Referred From: https://scholar.google.com/citations?user=YBsaoVAAAAAJ&hl=en

Cited by
Citations 5292
h-index 39
i10-index 119
Recommended Journals
Open Access Journals